Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by HaEmek Medical Center, Israel.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT01270334
First received: January 4, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

vaginal PH has an effect on the effectiveness of treatment with misoprostol given vaginally for missed abortions in the first trimester


Condition Intervention
MISED ABORTION- Vaginal PH
Other: PH meassurment

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Effect of Vaginal PH on Treatment Effectiveness With Misoprostol for First Trimester Missed Abortions

Resource links provided by NLM:


Further study details as provided by HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • treatment failure- need for D&C [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • side effects, need foe analgetics, time for compliting abortion [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: February 2011
Groups/Cohorts Assigned Interventions
ph above cutoff Other: PH meassurment
meassuring ph USING PROBE
PH under cutoff Other: PH meassurment
meassuring ph USING PROBE

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

women dignosed with missed abortion in the first trimester

Criteria

Inclusion

  • missed abortion under 8 weeks by sac diameter over 18 years old informed concent given

Exclusion Criteria:

  • missed abortion over 8 weeks hypersensitivity for PG vaginal bleeding suspected EUP IUD heart disease, HTN, cerebral vascular disease, epilepsy intrauterine infection clooting disorder under 18
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01270334

Contacts
Contact: shira baram, dr 972-4-6494035 shira_ba@clalit.org.il

Locations
Israel
Haemel Medical Center Not yet recruiting
Afula, Israel
Contact: shira baram, md    972-4-6494035      
Principal Investigator: shira baram, md         
Sponsors and Collaborators
HaEmek Medical Center, Israel
  More Information

No publications provided

Responsible Party: doctor baram shira, HaEmek Medical Center
ClinicalTrials.gov Identifier: NCT01270334     History of Changes
Other Study ID Numbers: cytoph
Study First Received: January 4, 2011
Last Updated: January 4, 2011
Health Authority: Israel- Health ministery, Israel:

Additional relevant MeSH terms:
Abortion, Missed
Abortion, Spontaneous
Pregnancy Complications
Misoprostol
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics

ClinicalTrials.gov processed this record on October 02, 2014